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Sphingomimetic multiple sclerosis 
drug FTY720 activates vesicular 
synaptobrevin and augments 
neuroendocrine secretion
Frederic D. Darios1,7, Jernej Jorgacevski  2,3, Ajda Flašker2, Robert Zorec2,3,  
Virginia García-Martinez4, José Villanueva4, Luis M. Gutiérrez4, Charlotte Leese5, Manjot Bal6, 
Elena Nosyreva6, Ege T. Kavalali6 & Bazbek Davletov1,5
Neurotransmission and secretion of hormones involve a sequence of protein/lipid interactions 
with lipid turnover impacting on vesicle trafficking and ultimately fusion of secretory vesicles with 
the plasma membrane. We previously demonstrated that sphingosine, a sphingolipid metabolite, 
promotes formation of the SNARE complex required for membrane fusion and also increases the 
rate of exocytosis in isolated nerve terminals, neuromuscular junctions, neuroendocrine cells and in 
hippocampal neurons. Recently a fungi-derived sphingosine homologue, FTY720, has been approved 
for treatment of multiple sclerosis. In its non-phosphorylated form FTY720 accumulates in the central 
nervous system, reaching high levels which could affect neuronal function. Considering close structural 
similarity of sphingosine and FTY720 we investigated whether FTY720 has an effect on regulated 
exocytosis. Our data demonstrate that FTY720 can activate vesicular synaptobrevin for SNARE 
complex formation and enhance exocytosis in neuroendocrine cells and neurons.
The sphingolipid signalling pathway plays an important role in the brain function and pathophysiology of 
diverse neurological diseases1–4. A synthetic analogue of sphingosine, FTY720 also known as fingolimod, has 
been investigated extensively for clinical use in the last decade and recently approved for the treatment of mul-
tiple sclerosis, the most common inflammatory disorder of the CNS5, 6. FTY720, when phosphorylated, binds 
to sphingosine-1-phosphate receptors and thereby causes lymphocyte egress leading to immunosuppression7, 8. 
Emerging data from experimental animal models suggest that fingolimod may have additional therapeutic appli-
cations. Recently, significant effects of FTY720 have been demonstrated in modulation of astrocyte function, 
neural excitability and anti-cancer effects9, 10. FTY720 readily crosses the blood brain barrier and accumulates 
in the CNS11, 12. FTY720 was found to be effective in treatment of animal models of cerebral ischemia, enceph-
alomyelitis, stroke, cerebral malaria and neurodegeneration12–18. The observed benefits were accompanied by 
improvement of electrophysiological abnormalities and synaptic function19–21. Recently it has been demonstrated 
that non-phosphorylated FTY720 can be taken up by neurons increasing long-term potentiation in electrophysi-
ological recordings from hippocampal slices22. Given the growing body of in-vivo experimentation with FTY720 
and its favourable safety profile there is a hope for translation of some of these findings for indications other than 
multiple sclerosis. Investigation of neuronal mechanisms which could be affected by application of FTY720 thus 
becomes an important line of research. Since sphingosine was recently shown to act as a stimulator of neuronal 
exocytosis23–25, it is conceivable that FTY720 could also affect release of neurotransmitters and hormones.
Communication between neurons and the release of hormones involve formation of protein complexes 
between the secretory vesicles and the plasma membrane, where vesicular synaptobrevin engages the plasma 
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membrane syntaxin/SNAP25 heterodimer26. Synaptobrevin, resident on synaptic vesicles and chromaffin gran-
ules, may not readily react with syntaxin and SNAP-2527, although an opposing view has been also put forward28. 
We recently reported that sphingosine, a releasable backbone of sphingolipids, can activate vesicular synaptobre-
vin for protein assembly and upregulates exocytosis in neuroendocrine cells and in hippocampal neurons23. Here 
we demonstrate that FTY720 is as effective as sphingosine in activating vesicular synaptobrevin and stimulating 
neuronal and neuroendocrine exocytosis.
Materials and Methods
Synaptic vesicle assays and synaptosomal glutamate release. Plasmids encoding glutathione 
S-transferase (GST) fusion proteins of rat syntaxin 1A (aa 1–261) and rat SNAP-25B were described previously29. 
Recombinant proteins were released from GST by incubating beads with thrombin, and proteins were further 
purified using a Superdex 200 column equilibrated in 100 mM NaCl, 20 mM HEPES (pH 7.3). Protein concentra-
tions were estimated using Coomassie Plus reagent (Pierce, Thermo Fisher Scientific Inc., Waltham, MA, USA). 
Synaptosomes were prepared from rat brains on a Ficoll (Pharmacia, Uppsala, Sweden) gradient as described 
previously30. For isolation of synaptic vesicles, synaptosomes were disrupted by the hypoosmotic shock (10 mM 
Hepes, pH 7.3). Synaptic membranes were removed by centrifugation for 20 min at 34,000 g at 4 °C. Supernatant, 
containing cytosol and synaptic vesicles, was mixed 1:1 (v/v) with Optiprep (Invitrogen Carlsbad, CA, USA), 
overlaid with 10 mM HEPES, 100 mM NaCl containing 40% Optiprep, and centrifuged for 1 h at 400,000 g at 4 °C. 
Synaptic vesicles were collected from the top of the gradient in a 120 µl volume and used in SNARE assembly at 
10 µg/reaction. Synaptic vesicles (10 µg) were incubated with premixed syntaxin1/SNAP-25 heterodimers (2 µg) 
in the presence of 50 µM sphingosine-mimetics (Biomol, Hamburg, Germany) for 30 min at 22 °C. Alternatively, 
synaptic vesicles (5 µg) were incubated in the presence of Glu-C protease (2.5 ng/µl) for 20 min at 37 °C. Reactions 
were stopped by the addition of SDS-containing sample buffer. SDS-resistant SNARE complexes were detected 
by SDS-PAGE followed by Western immunoblotting using an anti-synaptobrevin antibody (clone 69.1, Synaptic 
Systems, Germany). Anti-synaptophysin antibody was from Synaptic Systems, Germany.
For measurements of glutamate release, freshly-isolated synaptosomes were resuspended in synaptosomal 
buffer containing (in mM): 132 NaCl, 5 KCl, 20 HEPES, 1.2 NaH2PO4, 1.3 MgCl2, 0.15 Na2EGTA, 1 MgSO4, 5 
NaHCO3, 10 D-glucose (pH 7.2). Synaptosomes (1 mg protein/ml) were incubated for 10 min at 37 °C with an 
equal volume of synaptosomal buffer containing glutamate dehydrogenase (15 units/ml) and 3 mM NADP in the 
presence of either sphingosine-mimetic solution or vehicle, DMSO. Glutamate release was induced by addition 
of KCl (35 mM) in the presence of 2 mM CaCl2 and monitored by following fluorescence (excitation 340 nm, 
emission 460 nm) in black 96-well plates in Safire II spectrofluorometer (Tecan, Männedorf, Switzerland). 
Calcium-dependent release was calculated by subtracting the fluorescence signals obtained in the presence and 
absence of CaCl2.
Liposomal aggregation assay. Plasmid encoding GST fusion of rat synaptobrevin 2 (aa 1–96) was 
described previously29. Recombinant protein GST-synaptobrevin was eluted from glutathione-Sepharose beads 
by incubating beads with 10 mM glutathione, and the fusion protein was further purified using a Superdex 200 
column equilibrated in 100 mM NaCl, 20 mM HEPES (pH 7.3). Liposomes consisting of phosphatidylcholine/
phosphatidylserine (Avanti Polar Lipids) at a molar ratio of 75/25 were prepared by evaporation of chloroform/
methanol under nitrogen followed by resuspension in 100 mM NaCl, 20 mM HEPES (pH 7.3) and extrusion 
through 100 nm filter (Avanti Polar Lipids). 25 µl of GST-synaptobrevin (10 µM) was added to a 75 µl of liposomal 
solution (0.5 µg/µl) and following 90 sec, 25 µl of solution was added for the final concentration of 0, 10, 20 or 
50 µM FTY720. Spectrophotometric changes were recorded at 350 nm using a BioRad spectrophotometer.
Melanotroph cell experiments. Melanotroph cultures from the pituitary pars intermedia were pre-
pared from male Wistar rats as described previously31, 32 and maintained at 37 °C in 5% CO2 for up to 4 days. 
Membrane capacitance (Cm) was measured using the uncompensated whole-cell technique with a dual-phase 
lock-in patch-clamp amplifier (SWAM IIC, Celica, Ljubljana, Slovenia). Cells were observed under the Zeiss Axio 
observer A1 (Zeiss, Oberkochen, Germany) in the extracellular solution containing (in mM): 130 NaCl, 5 KCl, 
8 CaCl2, 1 MgCl2, 10 d-glucose, 10 HEPES (pH 7.2). Melanotrophs were voltage clamped at −70 mV and a sine 
wave voltage (1591 Hz, 1.11 mV RMS) was applied to the pipette (resistance of 2–5 MΩ) which were filled with 
the intracellular solution containing (in mM): 150 KCl, 2 MgCl2, 10 HEPES/KOH (pH 7.2), 2 Na2ATP, 2 EGTA, 
1.74 CaCl2 (yielding free [Ca2+] of 1 µM). Signals were acquired by Cell software (Celica, Ljubljana, Slovenia). 
Secretory responses were measured as a change in Cm (%) relative to the Cm determined immediately after the 
establishment of the whole-cell recording. We first recorded changes in Cm under spontaneous conditions for 70 s 
and then added FTY720 (Cayman Chemical, Ann Arbor, MI, USA)-containing solution or vehicle in the ratio 
(v/v) of 1:1. Changes in Cm were recorded for an additional 70 s.
Chromaffin cell experiments. Chromaffin cells were isolated from bovine adrenal glands by collagenase 
digestion and further purified by centrifugation on Percoll gradients as described previously33. The cells were 
maintained at a density of 150,000 cells/cm2 in Dulbecco’s modified Eagle’s medium supplemented with 10% 
fetal calf serum, 10 μM cytosine arabinoside, 10 μM 5-fluoro-2′-deoxyuridine, 50 IU/ml penicillin and 50 μg/
ml streptomycin. To study secretion from chromaffin cells, culture media was replaced by Krebs/HEPES, (K/H) 
basal solution containing (in mM): 134 NaCl, 4.7 KCl, 1.2 KH2PO4, 1.2 MgCl2, 2.5 CaCl2, 11 glucose, and 15 
HEPES (pH 7.4). Carbon-fiber electrodes with 14 µm diameter tips were used to monitor catecholamine release 
from individual chromaffin granules (Gil et al., 1998). Electrodes were positioned in close apposition to the cell 
surface using an Axiovert 135 inverted-stage microscope (Zeiss, Oberkochen, Germany) with mounting Hoffman 
optics (Modulation Optics, Greenvale, NY, USA). An amperometric potential of +650 mV versus an Ag/AgCl 
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bath reference electrode was applied using an Axopatch 200 A amplifier (Axon Instruments Inc. Foster City, CA, 
USA). Currents generated by catecholamine oxidation were digitized using an A/D converter and recorded using 
the Clampex program (Axon Instruments Inc. Foster City, CA, USA). Cells were depolarized using 59 mM high 
potassium-containing K/H solution which was applied through a valve-controlled puffer tip. After acquisition 
at 2 kHz, individual spike characteristics were analysed using the Quanta program which allows peak detection, 
integration and parameter calculations34. Only well-defined narrow peaks with amplitude higher than 5 pA and 
stable baseline were used for analysis, ensuring that the secretory events were acquired in the vicinity of the elec-
trodes where maximal catecholamine oxidation is achieved and that multipeaks are discarded from the analysis. 
The same electrodes were used for the control and FTY-720 treated cells to avoid possible variation.
Electrophysiology of Rat Hippocampal Neurons. Hippocampal neuronal cultures were prepared 
from postnatal day 0 to postnatal day 3 Sprague-Dawley rat pups as described35. The hippocampus was dis-
sected and dissociated cells were plated on glass coverslips and stored at 37 °C with 5% CO2 in a humidified 
incubator. We used a modified Tyrode’s solution containing (in mM): 145 NaCl, 4 KCl, 2 MgCl2, 10 glucose, 10 
HEPES, 2 CaCl2 (pH 7.4). Pyramidal neurons were whole-cell voltage clamped at −70 mV with borosilicate glass 
electrodes (3–5 MΩ). Electrode solutions contained (in mM) 105 Cs-methanesulphonate, 10 CsCl, 5 NaCl, 10 
HEPES, 20 TEA-Cl, 4 Mg-ATP, 0.3 GTP, 0.6 EGTA, 10 QX-314 (pH 7.3, osmolarity 290 mOsM). Cultured hip-
pocampal cells were visualized with an inverted microscope Zeiss Axiovert S100 (Zeiss, Oberkochen, Germany). 
Hippocampal cultures (10–21 days in vitro) were treated with FTY720 for 10 min at 22 °C, washed thoroughly 
and then recordings were performed. Recordings were made in whole-cell voltage-clamp mode and cells held 
at −70 mV. Extracellular solution contained (in mM): 150 NaCl, 4 KCl, 2 MgCl2, 10 glucose, 10 HEPES, and 2 
CaCl2, (pH 7.4, 310 mOsm). To isolate AMPA receptor currents induced by EPSCs, recordings were made in the 
presence of D-AP-5 (50 μM) and picrotoxin (PTX; 50 μM), to block NMDA and GABA-activated currents. The 
solution also had tetrodotoxin (TTX) (1 μM) in the external solution to suppress action potential firing. FTY720 
was dissolved to its final concentration (10 μM) in the extracellular solution. NBQX (10 μM) was used as a spe-
cific blocker of AMPA mEPSC. Intracellular solution contained (in mM): 115 Cs-MeSO3, 10 CsCl, 5 NaCl, 10 
HEPES, 0.6 EGTA, 20 tetraethylammonium-Cl, 4 Mg-ATP, 0.3 Na2GTP (pH 7.35, 300 mOsm). Currents were 
recorded with an Axopatch 200 B amplifier and pClamp 9.0 software (Molecular Devices, Sunnyvale, CA, USA). 
Recordings were filtered at 2 kHz and sampled at 10 kHz. All chemicals were from Sigma Aldrich (St Louis, MO, 
USA) unless otherwise stated and were of the highest purity available.
Statistical Analysis. Values are presented as mean ± SEM of the number of experiments indicated in the 
figure legends or at the top of each bar. Differences between samples were tested with statistical tests indicated in 
the corresponding figure legends and were considered significant when P < 0.05 (*).
Ethics Statement. Rats were obtained from Charles River and cared for in accordance with the International 
Guiding Principles for Biomedical Research Involving Animals developed by the Council for International 
Organizations of Medical Sciences. All methods were performed in accordance with the relevant guidelines and 
regulations. Specifically, we have followed the rules of Three R’s to reduce the impact of research on animals. 
The ex-vivo experiments using Wistar rats were approved by the Veterinary Administration of the Republic of 
Slovenia (Apr. No. 3440-29/2006 and 34401-29/2009/2). The ex-vivo experiments using Sprague-Dawley rats 
were approved by the institutional animal care and use committee (IACUC) protocols of the University of Texas 
Southwestern Medical Center (APN# 0866-06-05-1).
Results
In recent years, pharmaceutical companies demonstrated the therapeutic potential of a variety of positively 
charged lipid compounds including sphingosine mimetics, such as FTY720. We tested whether amine-containing 
positively-charged lipid compounds could upregulate vesicular synaptobrevin for SNARE complex formation 
as was reported recently for sphingosine23. Synaptic vesicles were purified from rat brain synaptosomes by flo-
tation and then incubated with synaptobrevin’s partner proteins – syntaxin and SNAP25 that normally reside 
in the plasma membrane. To probe synaptobrevin availability on synaptic vesicles both proteins were prepared 
recombinantly, without their membrane-interacting parts. When the soluble syntaxin/SNAP25 heterodimer was 
added to isolated synaptic vesicles, synaptobrevin migrated at its monomeric position as evidenced by Western 
immunoblotting (control, Fig. 1a), indicating that on the surface of synaptic vesicles synaptobrevin is inhibited. 
Interestingly, among the tested compounds, only FTY720, psychosine and thonzonium activated vesicular syn-
aptobrevin to engage syntaxin and SNAP25 (Fig. 1a,b). Psychosine (galactosylsphingosine) is a direct derivative 
of sphingosine and is known to accumulate in the brain tissue in Krabbe’s disease, a rare disorder caused by 
deficiency of the enzyme galactosylceramidase36. Thonzonium is an artificial surface-active agent which is used 
in topical anti-bacterial medications. FTY720, on the other hand, is prescribed for internal use and was shown to 
accumulate in the brain1. Like sphingosine, FTY720 is positively charged at physiological pH due to its tertiary 
amine group (pKa 7.8). Importantly, when phosphorylated, FTY720 did not stimulate SNARE assembly (Fig. 1a) 
suggesting that the positive charge of FTY720 is critical for activation of synaptobrevin.
Next, we compared the three active compounds on their ability to stimulate calcium-dependent exocytosis 
from isolated nerve endings obtained from rat brain. The compounds (20 µM) were added to rat brain synap-
tosomes for 10 minutes before addition of 35 mM KCl to trigger calcium-triggered glutamate release (Fig. 1c). 
Measure of end-point calcium-dependent release showed that only FTY720 stimulated glutamate release whereas 
compounds which cannot penetrate lipid membrane due to either a hydrophilic galactose group (psychosine) or 
a strong positive charge (thonzonium) had no effect. This suggests that FTY720 possesses unique characteris-
tics which are similar to sphingosine and thus we focused further investigation on this particular compound. A 
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titration experiment showed that FTY720 stimulated calcium-dependent glutamate release from rat brain synap-
tosomes in a dose-dependent manner with EC50 ~7 µM (Fig. 2a). In the SNARE assembly reaction, we observed 
similar but slightly lower sensitivity of synaptobrevin to FTY720 when using the isolated vesicle preparation 
(EC50 ~14 µM, Fig. 2b,c).
Next we investigated whether FTY720 can upregulate exocytosis in cultured melanotroph neuroendocrine 
cells isolated from the rat pituitary pars intermedia. We measured changes in the total plasma membrane area by 
the whole-cell membrane capacitance (Cm) technique, which reflects the balance of exocytosis and endocytosis37. 
Secretory responses were measured for 70 s, relative to the Cm, determined immediately after the establishment 
of the whole-cell recording (control conditions), or following the addition of either vehicle or FTY720 (Fig. 3a). 
A steady increase in Cm, due to 1 µM free calcium in the patch pipette solution, was unchanged after the addition 
of vehicle. In contrast, addition of FTY720 resulted in a pronounced increase in Cm, followed by a decline in Cm, 
most likely reflecting the activation of compensatory endocytosis (Fig. 3a,b). Dialyzed FTY720 at 10 µM, 20 µM 
and 50 µM concentrations enhanced the secretory response in melanotrophs by ~23%, ~85% and ~162%, respec-
tively (Fig. 3c). Considering the average diameter of secretory vesicles in melanotrophs being ~140 nm38, the 
acute application of 50 μM FTY720 in the presence of 1 µM [Ca2+]i led to fusion of approximately 1300 vesicles 
with the plasma membrane in 70 s in a single cell, whereas 1 µM [Ca2+]i by itself triggered fusion of only ~500 
vesicles in the same period of time.
Figure 1. FTY720 induces SNARE complex assembly and potentiates synaptic glutamate release. (a) 
Immunoblot showing that several positively charged compounds (50 μM, named structures outlined in the 
panel b) can accelerate SNARE complex assembly in the synaptic vesicle assay. (c) FTY720 exhibits the strongest 
positive effect on the glutamate release measured from rat brain synaptic endings, likely due to its superior 
membrane penetrating properties. All compounds were added at 20 µM 10 min before stimulation of glutamate 
release with 35 mM KCl (*P < 0.05, **P < 0.01, ANOVA).
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Fusion of vesicles with the plasma membrane may not always result in the extracellular release of signaling 
molecules39. For instance, the neck connecting the fusing vesicle with the plasma membrane (i.e. the fusion pore) 
may be too narrow to allow the release of signaling molecules from vesicles40. It is therefore important that Cm 
measurements are complemented with techniques that report the amount of secreted compound. To assess possi-
ble effects of FTY720 on the release of catecholamines from bovine chromaffin cells, we performed amperometric 
measurements, which allow characterisation of individual fusion events41. Catecholamine release from chroma-
ffin cells, pre-treated with FTY720 or not (controls), was stimulated by depolarization with high potassium solu-
tion (59 mM KCl). Representative amperometric traces obtained from control as well as FTY720-treated cells are 
shown in Fig. 4a. Averaging the integrated responses, obtained from 80 cells, demonstrated three-fold enhance-
ment of single vesicle secretion by FTY720 (Fig. 4b). Analysis of individual fusion events revealed transition to 
higher amplitude values with a 30% increase in the amplitude of the spikes and a two-fold increase in the amount 
of catecholamines released per event when compared to controls (1.9 × 106 vs 3.8 × 106 catecholamine molecules 
released, per event, in control and FTY720-treated cells, respectively) (Fig. 4c,d).
Figure 2. FTY720 accelerates SNARE complex assembly and glutamate release in a dose-dependent manner. 
(a) Graph showing dose-dependence of the FTY720 effect on KCl-triggered glutamate release from rat brain 
synaptosomes (**P < 0.01, ANOVA). (b) Immunoblot showing that synaptobrevin on synaptic vesicles engages 
syntaxin/SNAP-25 only in the presence of FTY720. (c) Graph showing the dose-dependence of the FTY720 
effect on SNARE assembly in the synaptic vesicle assay.
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The above experiments demonstrated that FTY720 can potentiate stimulated exocytosis. Our next goal was 
to learn if FTY720 could modulate the spontaneous release of neurotransmitters in the absence of stimulation. 
Therefore, we measured mEPSC activity in rat hippocampal neurons in culture. The application of FTY720 at 
10 µM caused ~3 fold increase in frequency of mEPSCs over the controls, as evidenced by representative traces 
of mEPSCs (Fig. 5a). FTY720 also slightly increased the mean amplitude of the unitary events by 6-8 pA but this 
increase was not significant (Fig. 5a). Importantly, the increase in mEPSC frequency could be suppressed by 
10 µM NBQX, a blocker of AMPA receptors, indicating the specific nature of FTY720 action (Fig. 5b). To examine 
whether the observed effects involve calcium-dependent mechanisms, we analysed the action of FTY720 on the 
mEPSC activity after incubation with BAPTA-AM, a cell-permeable calcium chelator. Neurons were pre-treated 
with 10 µM BAPTA-AM for 30 min and then mEPSCs were recorded. Figure 5c shows that although BAPTA-AM 
treatment caused a ~4-fold reduction in baseline mEPSC frequency, under the same conditions FTY720 applica-
tion still induced strong increase in the frequency of mEPSCs and a slight augmentation of the mean amplitude 
of the unitary events.
Next we addressed the behaviour of vesicular synaptobrevin in response to FTY720 in a more mechanistic 
detail. We used a limited proteolysis approach to test whether FTY720 increases availability of synaptobrevin to a 
proteolytic enzyme. We incubated purified synaptic vesicles in the presence of Glu-C protease, which hydrolyses 
proteins at glutamine residues, and estimated residual protein content by immunoblotting. Figure 6a shows that 
Glu-C enzyme was able to digest synaptobrevin more efficiently in the presence of FTY720 (50 µM). In contrast, 
synaptophysin amounts were not affected by the drug. Thus, FTY720 not only affects synaptobrevin’s availability 
for SNARE interactions but appears to influence it more generally. Next, we analysed whether synaptobrevin’s 
Figure 3. FTY720 enhances stimulated exocytosis in pituitary melanotrophs. (a) Representative traces of 
time-dependent changes in membrane capacitance (Cm), measured in control conditions (Con.) and after 
the addition of either vehicle (+Veh.) or FTY720 (50 μM). Whole-cell Cm measurements were performed in 
the presence of 1 μM calcium in the patch pipette. (b) The averaged changes in the derivative of Cm (Cm/dt) in 
control (Con.), vehicle-treated (+Veh.) and FTY720-treated (+FTY720) conditions. Note the transient increase 
of the Cm derivative following the addition of FTY720, which indicates enhanced rate of exocytosis (c), FTY720 
elicited a dose-dependent increase of Cm, measured 70 s after the addition of FTY720, at 10 μM, 20 μM and 
50 μM concentration (***P < 0.001, Mann–Whitney U-test).
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cytoplasmic part (aa 1–96) can interact with phospholipid membranes and whether FTY720 can disrupt such 
an interaction. We prepared liposomes containing phosphatidylcholine (75%) and phosphatidylserine (25%) 
and incubated them with a fusion protein consisting of glutathione-S-transferase (GST) and synaptobrevin (aa 
1–96). Since GST is a dimeric protein, binding of liposomes by synaptobrevin (aa 1–96) would cause liposo-
mal cross-linking which can be evidenced by an increase in absorbance42. Figure 6b shows that the addition of 
GST-synaptobrevin (aa 1–96) caused liposomal aggregation. Crucially, addition of FTY720 led to a dispersal of 
liposomal aggregates in a dose-dependent manner as evidenced by a gradual decrease in spectrophotometric 
signal, following the expected drop due to a dilution factor. Addition of the vehicle solution in a control reaction 
led only to the dilution-related drop. Thus, synaptobrevin’s cytoplasmic part not only interacts with phospholipids 
but this interaction can also be influenced by lipophilic factors, such as FTY720.
Discussion
Sphingomimetic FTY720 has been recently approved for treatment of multiple sclerosis, albeit with some side 
effects which include headaches, fatigue and gastrointestinal disturbance43, 44. FTY720 exhibits strong immuno-
suppressive effects and when phosphorylated it drives sequestration of circulating mature lymphocytes into the 
lymph nodes6. The diverse therapeutic potential of FTY720 may involve new, yet unrecognised effects of FTY720 
directly within the CNS. FTY720 readily penetrates into the CNS and accumulates in the brain and in the spinal 
cord12. The need for well-defined therapeutic targets for FTY720 and related drugs has been highlighted8. Recent 
studies demonstrated the role of FTY720 on specific functions of astrocytes such as cytoskeleton10, 45, vesicle 
traffic and calcium homeostasis9, 46. In PC12 neuronal model cells, micromolar concentrations of FTY720 acti-
vated intracellular protein phosphatase 2 A (PP2A), an important modulator of neuronal function47. FTY720 
was shown to rescue the functional deficits of synapses in an animal model of multiple sclerosis, suggesting that 
it can have a direct action in CNS21. In the current study, we identify a new target of FTY720 related to synap-
tic function, namely vesicular synaptobrevin, which plays a crucial role in the release of neurotransmitters and 
hormones48.
The synaptic vesicle assay for SNARE complex assembly23 confirmed FTY720 as a positive regulator of syn-
aptobrevin almost identically to sphingosine. Several complementary approaches measuring exocytosis demon-
strated that, in a micromolar range, FTY720 has a strong potentiating effect on secretion in several neurosecretory 
Figure 4. FTY720 enhances chromaffin cell exocytosis stimulated by 59 mM KCl. (a) Representative 
amperometric recordings obtained from cells stimulated by depolarization with a high potassium solution 
(K+) when pre-incubated or not with a 20 µM FTY720 solution for 15 min. (b) A graph showing the cumulative 
secretion obtained by integration of amperometric responses from control (n = 89) and FTY720-treated cells 
(n = 129). Averaged individual spikes in the form of amplitude distributions (c) and the mean amplitude ± SEM 
(d) demonstrate the effect of FTY720 on individual secretory events (**P < 0.005, Student’s t-test).
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cell models. This enhancement in secretion seems to be in agreement with the effects reported for sphingosine 
in a variety of cellular systems such as hippocampal neurons and pituitary melanotrophs23, lactotrophs24, and 
adrenal chromaffin cells25, 49. The structural analogy of FTY720 with sphingosine could underlie the observed 
recruitment of synaptobrevin for SNARE complex assembly thereby enhancing regulated exocytosis. Although 
our data do not rule out further effects of FTY720 which could contribute to enhanced exocytosis9, we would like 
to propose that this sphingomimetic drug can also uplift the cytoplasmic part of synaptobrevin thereby activating 
SNARE assembly for vesicle exocytosis. We do not necessarily envisage that FTY720 directly binds to synapto-
brevin – it is possible that after incorporation into the synaptic vesicle membrane the positively charged amphi-
philic FTY720 changes the interface between synaptobrevin and the negatively charged surface of the vesicular 
membrane. The stimulatory effect of FTY720 on synaptobrevin was observed when the drug reaches micromolar 
range. Pertinently, a study of intracellular accumulation of FTY720 demonstrated that micromolar levels are eas-
ily achievable50. Using LC-MS mass-spectrometry method the authors demonstrated that the lipophilic FTY720 
accumulated several hundredfold inside cells reaching micromolar concentrations. Such cellular accumulation 
may also explain slightly higher sensitivity of synaptosomal release to FTY720 when compared to the in vitro 
vesicular SNARE complex formation (Fig. 2). It is important to consider that FTY720 is administered internally 
at mg doses and thus micromolar concentrations can be reached locally simply following drug dissolving in a 
volume equivalent to a glass of water (1 mg/200 ml equates ~15 µM).
Interestingly, our data revealed that FTY720 not only increased the frequency of secretory events, but also aug-
mented the amount of neurotransmitters released in individual fusion events. Such increase in the spike ampli-
tudes was previously reported for sphingosine24, 49 emphasizing a similar effect of positively charged amphiphilic 
molecules on the single vesicle fusion events in neuroendocrine cells. It is also possible that the small increase 
Figure 5. FTY720 augments spontaneous mEPSC activity in rat hippocampal neuronal cultures. (a) 
Representative traces of mEPSCs for control neurons and neurons treated with 10 µM FTY720. A three-fold 
increase in synaptic mEPSC frequency was detected after application of FTY720 (p < 0.0001, t-test), n = 6 for 
control, n = 8 for FTY720. Only a small insignificant increase in mEPSC amplitudes was observed after FTY720 
application (control 21.2 ± 2; FTY720 24.8 ± 2). (b) The stimulating effect of FTY720 can be blocked by 10 µM 
NBQX, a specific antagonist of AMPA receptors. (c) Cell-permeable calcium chelator, BAPTA-AM does not 
block the stimulating effect of FTY720 on neuronal mEPSC frequency but reduces basal mEPSCs frequency. 
Application of FTY720 significantly increased mEPSC frequency in neurons pre-treated with BAPTA-AM 
(p < 0.0001, t-test), n = 5 for control, n = 9 for FTY720. 20% increase in mEPSC amplitudes was observed in the 
presence of BAPTA-AM (control 20.7 ± 1; FTY720 24.9 ± 2).
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in mEPSC amplitudes observed after FTY720 treatment in hippocampal neurons reflects a postsynaptic role 
for synaptobrevin in AMPA receptor trafficking. Specifically, the increased amplitude of mEPSCs upon FTY720 
action could be caused by an increase in the number of glutamate receptors on postsynaptic densities leading to 
increased amplitude of mEPSCs. Recent experiments showed that postsynaptic AMPA receptor insertion requires 
synaptobrevin-dependent fusion of receptor-laden vesicles with the postsynaptic plasma membrane51, 52.
Together, our data reveal FTY720-triggered enhancement in vesicular fusion in neurons and neuroendo-
crine cells, urging further investigations of lipid regulators as novel therapeutics for neurological disease, espe-
cially because lipid-based drugs readily cross the blood-brain barrier and could accumulate in the brain tissue. 
FTY720 has been proposed to have potential therapeutic applications in models of Alzheimer’s disease, in cer-
ebral malaria, or cerebral ischemia11. Our data therefore provide novel insights into the intracellular actions of 
Figure 6. FTY720 disrupts the interaction of the cytosolic part of synaptobrevin with phospholipid 
membranes. (a) Immunoblot showing that native synaptobrevin in rat brain synaptic vesicles (5 µg protein) 
exhibits faster degradation by GluC protease (2.5 ng/µl) in the presence of FTY720 (50 µM). Synaptophysin 
immunostaining indicates no change in its proteolytic degradation suggesting a specific action of FTY720 on 
synaptobrevin (**P < 0.005, ANOVA, n = 3). (b) Graph showing that addition of dimeric GST-synaptobrevin 
(aa 1–96) causes aggregation of phospholipid liposomes as evidenced by a gradual increase of absorbance 
at 350 nm (Abs350). The aggregated state can be reversed by the addition of FTY720 solution at the indicated 
concentrations. In the absence of FTY720, only a drop due to the dilution factor is observed.
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FTY720 and may contribute to better understanding of the beneficial action of FTY720 and its side-effects in a 
variety of neurological conditions. More investigations will need to be carried out to determine the exact binding 
mechanism by which FTY720 influences synaptobrevin’s interaction with phospholipid membranes and whether 
it affects other synaptic players and neuronal processes.
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